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A relatively new approach in the treatment of speciﬁc wounds in animal models and in patients with type A botulinum toxin is
the focus of this paper. The indications or conditions include traumatic wounds (experimental and clinical), surgical (incision)
wounds, and wounds such as ﬁssures and ulcers that are signs/symptoms of disease or other processes. An objective was to
conduct systematic literature searches and take note of the reactions involved in the healing process and identify corresponding
pharmacokinetic data. From several case reports, we developed a qualitative model of how botulinum toxin disrupts the vicious
cycle of muscle spasm, pain, inﬂammation, decreased blood ﬂow, and ischemia. We transformed this model into a minimal kinetic
scheme for healing chronic wounds. The model helped us to estimate the rate of decline of this toxin’s therapeutic eﬀect by
calculating the rate of recurrence of clinical symptoms after a wound-healing treatment with this neurotoxin.
1.Introduction
As characterized by Hanchanale and coworkers [1], the
perception of botulinum toxin A has been transformed
“from poison to a healing agent.” Much of our present
knowledge about this toxin comes from the toxicological
literature. Information concerning botulinum neurotoxin
serotypes,molecularstructures,substratespeciﬁcities,mech-
anisms of zinc-dependent peptide hydrolysis, ion channel
formation, and other detailed topics has been extensively
reviewed [2–4]. Of the seven immunologically distinct
serotypes (A–F) from Clostridium botulinum and several
other species, type A is the best characterized and is among
the most potent of all toxins. The neurotoxin is initially
expressed as a single polypeptide of nearly 1300 amino
acid residues (MW ∼150kDa). Crude toxin extracts (MW
ranges from ∼300 to 900kDa) contain several nontoxic
ancillary proteins that form a complex with the neurotoxin.
When ingested, these additional proteins are thought to
protect the neurotoxin against austere environments such
as those found in the certain regions of the gastrointestinal
tract [5]. The neurotoxin is posttranslationally modiﬁed
to form two chains that are covalently bridged with a
disulﬁde bond. The light (L) chain (MW ∼50kDa) has zinc-
dependent proteolytic activity, while the heavy (H) chain
contains the translocation and binding domains. Subsequent
to binding to speciﬁc receptors (SV2) [6] at peripheral
cholinergic nerve terminals, the receptor-toxin complex is
internalized into a membrane-bound compartment that
undergoes a drop in pH. This acidiﬁcation initiates a series
of interrelated reactions. Conformational changes occur that
allow the insertion of the H-chain into this compartment’s
membrane. As a result, the disulﬁde bond that links the
L and H chains is reduced, an ion channel is formed,
and the presumed proteolytic active moiety, the L-chain, is
translocated into the neuroplasm. When the type A toxin2 Journal of Toxicology
substrate, SNAP-25, is selectively cleaved, synaptic vesicle-
mediated neurotransmission is blocked that could eventually
lead to fatal paralysis.
Since the 1980s, the therapeutic potential of this toxin
has been exploited. Extraocular muscles have been injected
with the partially puriﬁed neurotoxin as an adjunct or
alternativetosurgicalcorrectionintreatingstrabismus[7,8].
The chemodenervation eﬀects of this most poisonous of
poisons [9] have been used to relax hyperkinetic striated
muscle groups to diminish the eﬀects of dystonia and related
diseases [10]. Currently, BOTOX has been approved by
the U.S. Food and Drug Administration (FDA) for the
following indications: strabismus, blepharospasm, cervical
dystonia, upper limb spasticity, maxillary hyperhidrosis,
chronic migraine [11], and urinary incontinence [12].
These indications along with the temporary enhancement
in the appearance (cosmesis) with BOTOX COSMETIC of
moderate to severe wrinkles in adults [13, 14] introduces
the theme of muscle immobilization in terms of a desired
therapeuticoutcome.Immobilizationhasbeencharacterized
asafundamentalprincipleofwoundhealing[15].Advantage
has also been taken of this toxin’s chemoimmobilization
property to improve the healing of wounds.
In contrast to the relatively vast amounts of information
regarding this toxin’s structure and mechanism of action,
the newer, oﬀ-label uses for botulinum toxin have been
less extensively reviewed. To gain further insight regarding
the scope of these eﬀorts, we have gathered and exam-
ined biomedical research articles by conducting systematic
searches of the relevant literature in PubMed, in a manner
similar to that of Steele and Madoﬀ [16]. We have examined
studies that range from descriptive observations to random-
ized controlled clinical trials to obtain more information
about the components and processes involved in wound
healing and the related time courses of action of botulinum
toxin A.
The processes observed clinically on the wound healing
eﬀects of the type A toxin are at an early stage of our
understanding. This proposal is substantiated by evidence-
based reviews that critically evaluate this toxin’s eﬀects with
diﬀerent indications [17, 18]. We previously noted [19, 20]
that only a few clinical studies have focused on kinetic
analyses. Constructing even partial models for the clinically
observedeﬀectsbythistoxinremainsachallenge.Toadvance
our understanding, we have selected some of those clinical
studies that have examined the timing of this toxin’s eﬀects.
2. Methods
2.1. Literature Searches. botXminer, the botulinum refer-
ence tool of clostridial neurotoxin citations in Entrez-
PubMed/MEDLINE [20], was initially used to search in
article titles, abstracts, and MeSH headings for the words
“wound” and “heal” or “healing.” A more extensive list of
29 wound-related keywords was then generated: anal, angio-
genesis, collagen, cytokine, ﬁbroblast, ﬁbroblastic, ﬁbrosis,
ﬁssure, ﬂap, glycosaminoglycan, heal, healing, hemorrhoid,
hemorrhoidectomy, hypertrophic, incision, inﬂammation,
inﬂammatory, keloid, lesion, repair, scar, scarring, sphinc-
terotomy, surgical, tendon, tensile, ulcer, and wound. This
controlled vocabulary was used in the batch mode [21]t o
search botXminer for additional related citations. Another
set of ﬁlter terms were used to ﬁnd time-course-related
information about this toxin. This set included 26 terms:
clearance, day, decay, decline, delay, diﬀusion, duration, fol-
low up, frequency, hour, hr, interval, kinetic, latency, minute,
month, onset, period, persistence, recurrence, repeat, resis-
tance, sec, time, week, and year.
Within the two lists in the batch matrix search,
(a1,a2,...,am)a n d( b1,b2,...,bn), the terms undergo the
ORoperation(

)whichcanberepresentedinageneralform
of (a1 OR a2 OR, etc.). In addition, the lists are combined
with the AND operation (

)[ 21] which results in a batch
query that can be represented by

a1

a2

···am



b1

b2

···bn

. (1)
Summaries from the two sets of terms were returned by
botXminer in the form of tables, histograms, and lists.
Lists of citations were subsequently manually examined.
Additional keywords and phrases within the more than 70
downloaded text ﬁles were automatically searched with ﬁle
search assistant (v. 3.1, 2009, AKS-Labs, Raleigh, NC, USA).
2.2. Analysis of Kinetic Data. Data from the clinical literature
that were analyzed were ﬁtted to an exponential function
y = y0 +(a)exp

−kdecayt
	
,( 2 )
where y is the cumulative number of patients who are free
of symptoms at time = t, y0 is the cumulative number
of patients who are symptom-free at t =∞ , a is a
preexponential constant, and kdecay is the rate constant for
the decay of this response. SigmaPlot (v. 11.0, 2008, Systat
Software, Inc. Chicago, Ill, USA) was used to conduct a
least-squared ﬁt for the values of y0, a,a n dkdecay. The 95%
conﬁdence intervals for y values were also calculated. This
equation is commonly used for simulating the decay rate of
a reactant from a single model compartment.
2.3. Nomenclature. The FDA has approved generic, nonpro-
prietary names for commercial formulations of botulinum
toxin [22–24]. For botulinum toxin type A, BOTOX (Aller-
gan, Calif, USA) is onabotulinumtoxinA, DYSPORT (Ipsen
Biopharm Limited Co., UK) is abobotulinumtoxinA, and
Xeomin (Merz Pharma GmbH & Co KGaA., Germany)
is incobotulinumtoxinA [25]. For botulinum toxin type
B, MYOBLOC/NeuroBloc (Solstice Neuroscience, Inc., Pa,
USA;EisaiLtd.,UK)isnowrimabotulinumtoxinB[26].The
changes in nomenclature emphasize the diﬀerent potencies
and the noninterchangeable unit dosages of these distinct
brand name products. As reviewed by Alberto [24], these
distinctions in names emphasize the diﬀerences in manu-
facturing and formulation techniques that may contribute
to diﬀerences in the pharmacokinetics, eﬃcacy, safety, and
antigenicity among these products.Journal of Toxicology 3
In the present paper, partially puriﬁed toxin with non-
toxic or accessory proteins is referred to as botulinum toxin
type A to distinguish it from botulinum neurotoxin A
(BoNT/A), the pure holotoxin.
2.4. Sources of Error and Uncertainty. The lists of selective
k e y w o r d sa r en o ti n t e n d e dt ob ee x h a u s t i v eb u ts e r v ea sa
starting point for the present work. Additional terms, such
as proctology and coloproctology [27], can be used in more
comprehensive studies.
Software development involves veriﬁcation and valida-
tion. Veriﬁcation conﬁrms that, for example, the equations
being coded are producing the correct calculations. Software
can be validated when it can model the results that best
ﬁt existing data, and is subsequently reinforced by further
data obtained experimentally. For kinetically related clinical
problems, the underlying processes that need to be included
are still uncertain. Furthermore, mathematical models are
not designed to replace validation by basic research experi-
ments or clinical observations. Rather, models are meant to
enhance validation procedures by providing stimuli for new
ideas, hypotheses, and perspectives on the problems being
examined.
3. Results andDiscussion
3.1. Literature Search for Botulinum Toxin A and Wound
Healing. ApreliminarysearchofbotXminer,usingthequery
“wound AND (heal OR healing)” for years 1980–2010,
returned over 150 citations about half of which were true
positives due to the large number of references related
to tetanus (false positives). From the list of true positive
citations, additional keywords were identiﬁed.
A variety of indications were found, in which botulinum
toxin A has been used for wound healing and related condi-
tions.Theseexamplesincludedexperimentalcutaneousscars
in animal models [15, 28] and in clinical studies: chronic
anal ﬁssures [29, 30], cleft lip surgical repair [31], traumatic
headlacerationsorelectiveexcisionsofforeheadmasses[32],
focal fold granuloma [33], hypertrophic scarring [34], pres-
sure ulcers [35, 36], Raynaud’s phenomenon (vasospastic
ischemia of the digits, digital ischemia, including chronic
ulcers) [37], and self-mutilation injuries in Lesch-Nyhan
syndrome [38]. Another healing application of botulinum
toxin A, referred to as protective ptosis, is used against
persistent corneal ulcers, burns, and other ophthalmic-
related problems [39, 40].
Conductingamatrixbatchsearchinwhich“tetanus”was
ﬁltered out, using 26 time-related terms along with the 29
wound healing-related terms, yielded 671 unique citations.
From this ﬁltered output, we concentrated on references
dealing with wound conditions and indications in which
botulinum has been used for therapeutic purposes in which
some mechanistic, dosage, and/or kinetic information was
also available (Methods, Figure 1).
3.2. Botulinum Toxin A and the Components of the Heal-
ing Process. The normal wound-healing process has been
described as being comprised of four overlapping phases:
haemostasis, inﬂammation, tissue proliferation, and remod-
eling [41]. If any of these processes are disrupted, healing is
impeded leading to a chronic wound state. The interference
by botulinum toxin in reducing muscle movement has
helped to deﬁne healing phases further. For example, a
vicious cycle involving inﬂammation, pain, and muscle
spasm was ﬁrst noted to be the underlying cause for the
development of chronic anal ﬁssures [29, 42]. Subsequently,
low blood ﬂow and ischemia were added to this cycle [43–
45]. Additional components of the healing process have been
identiﬁed for other conditions as presented in this section.
Scar formation is a hallmark of wound healing, and
it usually causes signiﬁcant physical, psychological, and
cosmetic problems. Hypertrophic scarring is a common,
refractory dermal disease that is manifested by the abnormal
appearance of wound healing which can be the result of
diﬀerent types of injuries [34, 46, 47]. In the study by Xiao
et al. [46], 19 patients were treated once a month over 3
months with 1.8–35U botulinum toxin A (Hengli/CBTX-
A, Lanzou Biochemical Co., China [48]). Improvements in
wound healing were based on subjective grading by patients
and plastic surgeons. Scores were assigned before treatment
for the associated erythema, pliability (lesion softening), and
the severity of itching. After a 6-month followup of the
19 patients participating in that study, 15 gave an overall
assessment of their lesion improvement as “good,” and seven
others rated their improvement as “excellent.” Some critical
comments provided by the authors included the lack of
control subjects, the study was not double blinded, and
a small patient population size. Finally, there was only a
relatively short follow-up time of 6 months so that no
determination of the total time course of toxin action could
be established.
A number of quantitative parameters may be accessed
to evaluate the eﬀectiveness of wound healing by botulinum
toxin A. Increased metabolic activity and inﬂammation
during the healing process induce muscle contractions
around the edges of the skin wound [32, 46]. The major role
of botulinum toxin A in this healing process is to prevent the
repeated, small contractions that produce “microtraumas”
near the hypertrophic scar and thereby decrease the tensile
force (muscle activity) during scar formation. Traditional
surgical techniques that align incisions along Langer’s lines
do not prevent repeated contractions [15]. The development
of ﬁbrosis also involves the deposition of extracellular
collagen and glycosaminoglycans that can cause the scar to
hypertrophy, invert, and become hyperpigmented resulting
in poor color matching of this tissue with the neighboring
skin [15, 28]. Other parameters for wound healing include
size of wound, amount of and inﬁltration of inﬂammatory
cells, blood vessel proliferation, and wound thickness [28].
Additionalcellularandmolecularmechanismsofhealing
by the formation of scar tissue (traumatic cicatrisation)
are beginning to be elucidated [46]. Transforming growth
factor β1( T G F -β1) is a ﬁbrotic cytokine that stimulates
cellular growth, diﬀerentiation, and adherence and leads
to the collagen deposition. This cytokine initiates these
processes by extracellularly binding to a coupled pair of4 Journal of Toxicology
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Figure 1:ExampleoutputfromabotXminerdatabasesearch.Thenumbersofbotulinumtoxincitationsareshownforeachofthecombined
29 wound-healing (ﬁrst term) and 26 time-related terms (legend) that were associated with 671 unique citations. The wound-related
keywordsassociatedwith“botulinum”areassociatedwithhistogramsthatrepresentthediﬀerentnumbersofarticlesfoundinthesemultiple
searches. The color-coded, time-related keywords used in these searches are simultaneously displayed in these histograms. Each “a...”i nt h e
left-hand labels signiﬁes “and botulinum.”
serine-threonine kinases. On binding, one receptor recruits
and phosphorylates the other. This signaling pathway even-
tually stimulates transcription of the collagen gene and the
formation of hypertrophic scars. Because human ﬁbroblasts
derived from hypertrophic scars overexpress and secrete
TGF-β1, another wound-healing eﬀect of botulinum toxin A
has been speculated to be inhibiting the secretion of TGF-
β1[ 47]. Similarly, suramin, an antiﬁbrotic polysulfonated
naphthylurea compound, has been reported to promote
wound healing by antagonizing TFG-β1i nm u s c l e - d e r i v e d
ﬁbroblasts [49].
The circulatory system is also aﬀected by the apparent
ability of botulinum toxin to enhance wound healing.
Using a rat model for wounds, Yoo’s group [50]o b s e r v e d
that pretreatment with botulinum toxin A increased dorsal
skin ﬂap survival and concluded that this process was
caused by increased perfusion. Because this toxin inhibits
secretion of norepinephrine from sympathetic vasodilatorJournal of Toxicology 5
Botulinum toxin A disrupts the vicious 
pathway cycle that delays/prevents wound healing
Wound
Local muscle 
spasms/pain
Botulinum toxin A
Decreased blood ﬂow
Vicious cycle
inﬂammation
Ischemia→
Figure 2: Botulinum toxin is depicted to disrupt the vicious
pathway cycle that delays or prevents the healing of moderate
wounds. This cycle involving spasm, pain, diminished blood ﬂow,
ischemia,andinﬂammationisblockedbytheinhibitionofchemical
transmission at neuromuscular junctions by botulinum toxin A
[29, 42, 43]. Dashed line is inhibitory action.
andvasoconstrictorneurons[51,52],theeﬀectofbotulinum
toxin A may involve increased perfusion by decreasing sym-
pathetic vasoconstriction in the skin ﬂaps, thus promoting
skin ﬂap survival.
3.3. Kinetic Data for Onset and Duration of Healing Eﬀects
Produced by Botulinum Toxin A. T h ep r o t e c t i v ee ﬀects of
botulinum toxin-induced ptosis have been used for the
conditions of recalcitrant corneal ulcers and other surface
disorders as an alternative to the surgical practice of par-
tially sewing the eyelids together (tarsorrhaphy) [39]. This
secondary healing eﬀect is produced when botulinum toxin
A is injected into eye muscles, typically the levator palpebrae
superioris (LPS) muscles [53]. This therapeutic application
has been the subject of studies that have also generated
kinetic data [39]. From an open-label, multicentered study
with 16 ophthalmic patients who received 5U BOTOX in the
LPS muscle, the time to “suitable” ptosis was 4.0 ± 0.5 days
(mean ± SE, range: 2–8 days), and the duration of this ptosis
was 46.0 ± 12 days (1–206 days) [39]. A similar number
of patients who received a single, lower dose (2.5U) had a
comparable mean time to ptosis (3.6 days) and a shorter,
meanduration(16days).Diplopiawastheonlyadverseeﬀect
experienced by ﬁve patients. Although statistical analyses
with more patients are required to make more deﬁnitive
conclusions, these trends are not unexpected but are, nev-
ertheless, remarkable because a twofold change of a low dose
apparently resulted in appreciable diﬀerences in duration.
3.4.KineticAnalysisof Recurrenceof Symptoms. Chronic anal
ﬁssure (CAF) is a painful condition caused by spasms of the
internal sphincter smooth muscles. The traditional surgical
approach has been sphincterotomy that can result in the
adverse eﬀect of incontinence [30]. Traditional nonsurgical
approaches that have been used include sitz bath, topical
anaesthesia, nitroglycerin, isosorbide dinitrate, nifedipine,
Diltiazem, L-arginine gel, hyperbaric oxygen, and botulinum
toxin A [43]. The ﬁrst use of botulinum toxin as a medical
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Figure 3: Time course of recurrence of CAF symptoms in some
patients (22 of 53) in a 42-month follow-up study [55]. Initially
(t = 0, i.e., 6 months after injection), all 53 patients were symptom-
free for 6 months after injection of 10–20U BOTOX. The ﬁtted
values from (2)( s e et e x t )a r ey0 = 29.2, a = 24.4, and kdecay =
0.85 years−1.T h ey-axis represents the number of symptom-free
patients. Dashed line is ﬁtted data; solid lines are 95% C.I.
alternative for CAF was conducted by Jost and Schimrigk
[29]. For this indication, we chose what has been described
asoneofthelongestfollow-upstudiesusingbotulinumtoxin
(type A) in the treatment of CAF [54].
We analyzed data for the time course of recurrence of
CAF symptoms in patients in a 42-month follow-up study
[55, Table 1]. As illustrated in Figure 3, at the beginning of
the followup (at t = 0), all 53 patients were symptom-free
for 6 months after one to two injections of 10–20U BOTOX.
Subsequently,22of53patientsshowedarecurrenceofsymp-
toms. Most patients (31 of 53) did not undergo recurrence
indicating that they remained healed during this follow-up
period. From the nonlinear ﬁt of these data to (2), the ﬁtted
values ± SEMs are y0 = 29.2 ± 1.2, a = 24.4 ± 1.3. The kdecay
(decay rate constant) is 7.08 × 10−2± 1.07 × 10−2 month−1,
1.64 × 10−6min−1 (see below), or 0.85 years−1 (see Table 1).
Thevalueof1/kdecay orτ is14.1months,andthecorrespond-
ing value of t1/2(= τ ln2) is 9.8 months or 294 days.
The long-term success rate was only 31/53 (58%) or
a 42% rate of recurrence [30]. From Arroyo’s group [54],
recurrence rate of 12% occurred initially, and a rate of 53%
at the 3-year follow-up point. Bilateral ﬁssurectomies of the
internal anal sphincter combined with toxin injections [56]
have been reported to have a high success rate although the
follow-uptimeinthatstudywaslimitedto1year.Also,itwas
notdeterminedwhethersurgeryitselfproducedasimilarrate
of healing.
An interpretation of the single exponential decay curve
during the 42-month followup (Figure 3) is that it reﬂects a
zero-order elimination or inactivation step of the persistent,
intraneuronally located toxin [57]. This step is described
by the rate constant of decay, kdecay,i nFigure 4 and ke
in a previous publication [58]. The table summarizes the
processes displayed in Figure 4 and highlights the recurrence
of symptoms that may be used to gauge the slow elimination6 Journal of Toxicology
Table 1:Summaryofprocessesinvolvedinwoundhealingasdescribedintext.Recurrenceofsymptomsresultsfromlong-termobservations
[55] was analyzed in the present paper and is highlighted in bold.
Parameter Relative rates Rate constant symbol Units Value
Onset of initial wounding Very fast k1 msec−1 or sec−1 N.A.a
Development of chronic wound Moderate k2 days−1 or weeks−1 N.A.
Healing of acute wound Slow k3 weeks−1 or months−1 N.A.
Healing of chronic wound Very slow k4 years−1 N.A.
Recurrence of symptoms[55],[Figure 3]V e r y s l o w k decay years−1 0.85
4-step reaction [19]
Diﬀusion toxin to receptors Moderate k5 min−1 0.001
Binding of toxin Fast kB min−1 0.058
Translocation of toxin Fast kT min−1 0.141
Toxic reaction (lysis) Fast kL min−1 0.013
aN.A., because data are not presently available, order of magnitude estimates are given.
k1 ( m so rs ) −1
k4 (years)−1
k2 (days-weeks)−1
k5 (1-2 days)−1
kdecay very slow
k3 (weeks or months)−1
Very fast wounding
Botulinum toxin A
(4-step reaction)
Normal tissue
Chronic wound
(vicious cycle)
Initial wound
Very slow healing
Slow healing
Moderate rate
of chronic wound (0.85 years)−1
(k1 ≫ k5 >k 2 >
k3 ≫ kdecay ∼ k4)
Figure 4: A minimal kinetic model for enhanced wound healing with botulinum toxin. Wounding of the normal tissue state is assumed to
occur most rapidly leading to an initial wound state of the tissue. Healing from a signiﬁcant wound is typically a slow process taking weeks
or months. In the meantime, without treatment, this system enters, at a moderate rate, into a vicious cycle state (Figure 2) from which its
escape represents a very slow healing process. With botulinum toxin treatment, this cycle is blocked thus allowing the tissue to return to
the normal state by the slow healing route. The four-step reaction of toxin binding, translocation, internalization, and toxicity is described
elsewhere [19]. A competing reaction is depicted as the slow decay or the inactivation rate of this toxin (kdecay) that leads to a recurrence of
symptoms.
or inactivation of the type A botulinum toxin. Notably, this
rate may be comparable to the slow rates of healing of some
chronic wounds.
Alternatively, the long-lived toxic eﬀect may be related to
the rate of restoration of intact SNAP-25 intracellular levels
or a combination of a slow degradation and a persistent
inhibitory action of the SNAP-25 BoNT/A cleavage product
[59]. The value of t1/2 of 294 days is comparable to the
recurrencetimesof444 ±132days(mean ±S.D.;range270–
718 days [60]) for achalasia patients after receiving a single
injection of 80U BOTOX. On the other hand, our calculated
decay rate constant of 1.64 × 10−6min−1 is about 1000 times
slower than the estimated rate constant for decay of eﬃcacy
(1.1 × 10−3min−1) in a single dystonic patient [58, 61, 62].
This diﬀerence may be due to several factors, among which
are the diﬀerent patient populations, the muscles being
injected, the conditions being treated, and the assessment
methods.
4. FutureDirections
While the above studies show encouraging trends in support
of using botulinum toxin A in wound-healing paradigms,
additional studies are necessary. Overall, more prospective
clinical studies of these treatments with botulinum toxin A
are needed. Evidence from blinded, randomized, placebo-
controlled, multicentered studies will help determine if theseJournal of Toxicology 7
toxin treatments have signiﬁcant beneﬁt and if the minimal
adverse reactions can be sustained.
Future trials should also use larger populations of more
homogeneous (standardized) patients and control subjects,
plan to examine long-term outcomes, and conduct cost-
beneﬁt analyses [63]. Although randomized controlled trials
are considered the gold standard of clinical research [64],
assessingthemusingcriteriaforstandardizingphaseIIItrials
remains a substantial challenge [65]. Moreover, there is also
aneedforadditional controlledstudiestoclearlyestablishan
advantage of botulinum products over other methods.
Retrospective meta-analysis studies are also needed for
all of these new treatments. An outcome of one of these
analyses was the low probability that type A botulinum
toxin or calcium channel blockers were found to be more
eﬀective in treating CAF than nitroglycerin ointment in 182
patients [30]. Another example is Shao et al.’s analysis [44]
which determined that for 279 CAF patients the traditional
surgical procedure of lateral internal sphincterotomy (LIS)
was more eﬀective than BOTOX in healing chronic anal
ﬁssure. While LIS produced a higher rate of minor anal
incontinence, botulinum toxin was associated with a higher
rate of recurrent disease. For those patients who had a
high risk of incontinence, local injection of the toxin was
considered appropriate.
Computational modeling and simulation studies at
diﬀerent levels of granularity (i.e., detail) should also be
beneﬁcial. Starting with existing minimal kinetic models
[19, 66], dose-dependent kinetic models could be developed
to predict the time course (onset, duration, and recurrence
of symptoms) and the extent of botulinum toxin A’s eﬀec-
tiveness. Kinetic models could help to identify what research
gaps exist and which ones can be experimentally or clinically
resolved. One gap that could be experimentally veriﬁed is to
determine if the intracellular diﬀusion of botulinum toxin A
[67] is inﬂuenced by other coinjected materials, for example,
epinephrine and local anesthetics (lidocaine, Xylocaine),
compounds that have been considered in controlling local
diﬀusion and predicting the extent of this toxin’s paralytic
eﬀect [15, 32].
As more realistic physiological-pharmacological models
a r ed e v e l o p e d ,m o r ef r e ep a r a m e t e r sa n dm o r es o u r c e so f
error, assumptions, and caveats will need to be evaluated.
Potentially confounding factors associated with wounds
include cell viability, alkali conditions [41], the generation
of reactive oxygen species, and inﬂammation that is related
to low blood ﬂow and ischemia [45]. Changes in the ion ﬂow
through transmembrane channels and in metabolism could
also have roles in wound healing. Another confounding
factor is the well-known, persistent muscle weakness (up to
5 years) that results from protracted patient immobilization
due to critical illness polyneuropathy or myopathy [68, 69].
This persisting weakness and residual neurologic deﬁcits are
likely due to denervation, combined with catabolic muscle
wasting and potential myopathic changes [68]. It remains
for future studies to diﬀerentiate these physiological deﬁcits
from botulinum toxin-induced eﬀects in either a botulism
patient or with therapeutic treatments with this toxin.
The tissues involved in the healing process in cytoskeletal
architectures and in membrane structures associated with
various organs also need to be considered. Neurophysio-
logical abnormalities, such as transient denervation-induced
muscle ﬁbrillations and presynaptic alterations producing
muscle fasciculations, may also need to be considered.
Other complicating factors in the healing process could also
involve the biomechanical dynamic properties of soft tissue
(e.g., stiﬀness) in response to stress and strain, and tissue
anisotropy (directionality of nonhomogeneous material).
5. Summary/Conclusions
This succinct review examines the soft tissue wound-healing
properties of botulinum toxin. When viewed from the
perspective of treating neurologic and other disorders, it is
noteworthy that the eﬃcacy of this toxin is predicted to be
transient as the toxin’s eﬀect wanes, while for wound healing,
a permanent resolution is expected. Further, with respect
to wound healing, the concept is described that for some
lesions, botulinum toxin interferes with the vicious cycle of
muscle spasm, pain, inﬂammation, decreased blood ﬂow,
and ischemia [43]. A reaction pathway scheme is outlined
to illustrate botulinum toxin’s involvement in stopping the
vicious cycle. A minimal kinetic scheme for healing chronic
wounds is also presented that includes diﬀerent macroscopic
states of soft tissue conditions (normal, initial wound, and
chronic wound), and quantitative estimates for the relevant
rate constants are provided. A deﬁnitive validation of the
results, that is, the minimal kinetic model for predicting the
beneﬁcial eﬀects of type A toxin, awaits additional clinical
data. Perhaps the most useful outcome is that our kinetic
model is capable of identifying a measurable gap (decay rate
oftoxin’seﬀect)inourattempttocomprehendhowcomplex,
interacting biological systems respond to environmental
stressors.
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